<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00222573</url>
  </required_header>
  <id_info>
    <org_study_id>COMMIT-CCS2</org_study_id>
    <secondary_id>H6RDCN0</secondary_id>
    <nct_id>NCT00222573</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial Infarction</brief_title>
  <official_title>Clopidogrel Or Metoprolol in Myocardial Infarction Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <brief_summary>
    <textblock>
      COMMIT/CCS2 is a large randomised trial of the effects of clopidogrel plus Aspirin versus&#xD;
      Aspirin alone in acute heart disease. Patients presenting within 24 hours of the onset of&#xD;
      suspected acute MI were potentially eligible provided they were thought to have ST elevation&#xD;
      or other ischaemic ECG abnormality with no clear indication for, or contraindication to,&#xD;
      trial treatment. All patients were to be given 162 mg ASA daily and, in addition, 75 mg&#xD;
      clopidogrel daily or matching placebo for 4 weeks or until prior discharge or death.&#xD;
      (Patients were also randomised separately in a 2 X 2 factorial design between metoprolol&#xD;
      versus placebo.) The two main study endpoints are death and the composite outcome of death,&#xD;
      non-fatal reinfarction or stroke during the scheduled treatment period in hospital.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clopidogrel&#xD;
&#xD;
      Despite considerable improvements in the emergency treatment of acute myocardial infarction&#xD;
      (MI), including the use of aspirin, early mortality and morbidity remain high. The&#xD;
      antiplatelet agent clopidogrel adds to the benefit of aspirin in acute coronary syndromes&#xD;
      without ST-segment elevation, but its effects on mortality and morbidity in patients with&#xD;
      ST-elevation MI were unclear.&#xD;
&#xD;
      45,852 patients admitted to 1250 hospitals within 24 hours of the onset of suspected acute MI&#xD;
      were randomly allocated to receive clopidogrel 75 mg daily or matching placebo (both in&#xD;
      addition to aspirin 162 mg daily). 93% had ST-segment elevation or bundle branch block, and&#xD;
      7% had ST-segment depression. Treatment was to continue until discharge or up to a maximum of&#xD;
      4 weeks in hospital (mean 15 days in survivors), and 93% completed it. The two pre-specified&#xD;
      co-primary outcomes were: (i) the composite of death, reinfarction or stroke; and (ii) death&#xD;
      from any cause during the scheduled treatment period. Comparisons were between all&#xD;
      clopidogrel-allocated and all placebo-allocated patients (ie, &quot;intention-to-treat&quot;), and used&#xD;
      the log-rank method.&#xD;
&#xD;
      Allocation to clopidogrel produced a highly significant 9% (95% CI 3-14) proportional&#xD;
      reduction in the primary composite outcome of death, reinfarction or stroke (2121 [9.2%]&#xD;
      clopidogrel vs 2310 [10.1%] placebo; p=0.002), corresponding to 9 (SE 3) fewer events per&#xD;
      1000 patients treated for about 2 weeks. There was also a significant 7% (95% CI 1-13)&#xD;
      proportional reduction in the co-primary outcome of any death (1726 [7.5%] vs 1845 [8.1%];&#xD;
      p=0.03). These effects on death, reinfarction and stroke appeared to be consistent across a&#xD;
      wide range of patients and independent of other treatments being used. Considering all&#xD;
      transfused, fatal or cerebral bleeds together, no significant excess risk was observed with&#xD;
      clopidogrel, either overall (134 [0.58%] vs 125 [0.55%]; p=0.59), or among patients aged 70&#xD;
      years or older (50 [0.84%] vs 43 [0.72%]; p=0.48) or among those given fibrinolytic therapy&#xD;
      (74 [0.65%] vs 72 [0.63%]; p=0.88).&#xD;
&#xD;
      In a wide range of patients with acute MI, adding clopidogrel 75 mg daily to aspirin and&#xD;
      other standard treatments (such as fibrinolytic therapy) reduces mortality and major vascular&#xD;
      events in hospital, without any material increase in major bleeding.&#xD;
&#xD;
      Metoprolol&#xD;
&#xD;
      Despite previous randomised trials of early beta-blocker therapy in the emergency treatment&#xD;
      of suspected acute myocardial infarction (MI), substantial uncertainty has persisted about&#xD;
      the value of adding it to currently standard interventions (eg, aspirin and fibrinolytic&#xD;
      therapy), and the balance of potential benefits and hazards was unclear even in high-risk&#xD;
      patients.&#xD;
&#xD;
      45852 patients admitted to 1250 hospitals within 24 hours of the onset of suspected acute MI&#xD;
      were randomly allocated to receive metoprolol (up to 15 mg intravenous followed by 200 mg&#xD;
      oral daily) or matching placebo. 93% had ST-segment elevation or bundle branch block, and 7%&#xD;
      had ST-segment depression. Treatment was to continue until discharge or up to a maximum of 4&#xD;
      weeks in hospital (mean 15 days in survivors), and 89% completed it. The two pre-specified&#xD;
      co-primary outcomes were: (i) the composite of death, reinfarction or cardiac arrest; and&#xD;
      (ii) death from any cause during the scheduled treatment period. Comparisons were between all&#xD;
      metoprolol-allocated and all placebo-allocated patients (ie, &quot;intention-to-treat&quot;), and used&#xD;
      the log-rank method.&#xD;
&#xD;
      Neither of the co-primary outcomes was significantly reduced by allocation to metoprolol. For&#xD;
      the primary composite outcome of death, reinfarction, or cardiac arrest, 2166 (9.4%) patients&#xD;
      had at least one such event among the 22 929 allocated metoprolol compared with 2261 (9.9%)&#xD;
      among the 22 923 allocated matching placebo (odds ratio [OR] 0.96 [95% CI 0.90-1.01]; p=0.1).&#xD;
      For the co-primary outcome of death alone, there were 1774 (7.7%) in the metoprolol group&#xD;
      versus 1797 (7.8%) in the placebo group (OR 0.99 [0.92-1.05]; p=0.69). Allocation to&#xD;
      metoprolol was associated with 5 fewer people having reinfarction (464 [2.0%] metoprolol vs&#xD;
      568 [2.5%] placebo; OR 0.82 [0.72-0.92]; p=0.001) and 5 fewer having ventricular fibrillation&#xD;
      (581 [2.5%] vs 698 [3.0%]; OR 0.83 [0.75-0.93]; p=0.001) per 1000 treated. Overall, these&#xD;
      reductions were counter-balanced by 11 more per 1000 allocated metoprolol developing&#xD;
      cardiogenic shock (1141 [5.0%] vs 885 [3.9%]; OR 1.30 [1.19-1.41]; p&lt;0.00001). The excess of&#xD;
      cardiogenic shock was chiefly during days 0-1 after hospitalisation, whereas the reductions&#xD;
      in reinfarction and ventricular fibrillation emerged more gradually. Consequently, the&#xD;
      overall effect on death, reinfarction, arrest or shock was significantly adverse during days&#xD;
      0-1 and significantly beneficial thereafter. There was substantial net hazard among&#xD;
      haemodynamically unstable patients and moderate net benefit among those who were relatively&#xD;
      stable, particularly after days 0-1.&#xD;
&#xD;
      The use of early beta-blocker therapy in acute MI reduces the risks of reinfarction and&#xD;
      ventricular fibrillation, but increases the risk of cardiogenic shock, especially during the&#xD;
      first day or so after hospitalisation. Consequently, it may generally be prudent to consider&#xD;
      starting beta-blocker therapy in hospital only when the haemodynamic condition following MI&#xD;
      has stabilized (and then, based on previous evidence, to continue such therapy long-term&#xD;
      following discharge).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1999</start_date>
  <completion_date>February 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death and the composite outcome of death, non-fatal reinfarction or stroke</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major cardiovascular events</measure>
  </secondary_outcome>
  <enrollment>46000</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel and metoprolol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients presenting with ST elevation, left bundle branch block or ST depression&#xD;
             within 24 hours of the onset of the symptoms of suspected acute MI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  clear indications for, or contraindications to, any of the study treatments&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rory Collins, Msc</last_name>
    <role>Study Chair</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lisheng Liu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institute of cardiovascular diseases, Fuwai hospital, Chinese academy of medical sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Cadiovascular diseases, Fuwai hospital, Chinese academy of medical sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Service Unit and Epidemiological Studies Unit</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.commit-ccs2.org</url>
    <description>study website</description>
  </link>
  <results_reference>
    <citation>Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, Xie JX, Liu LS; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005 Nov 5;366(9497):1622-32.</citation>
    <PMID>16271643</PMID>
  </results_reference>
  <results_reference>
    <citation>HÃ¼bner G, Golbik R, Meshalkina LE. A method for determination of transketolase activity based on the use of a pH indicator. Biochem Int. 1992 Mar;26(3):545-50.</citation>
    <PMID>1627164</PMID>
  </results_reference>
  <verification_date>March 2005</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>May 4, 2006</last_update_submitted>
  <last_update_submitted_qc>May 4, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2006</last_update_posted>
  <keyword>clopidogrel</keyword>
  <keyword>metoprolol</keyword>
  <keyword>myocardial infarction</keyword>
  <keyword>randomised trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

